Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling
Miriam Doepner(University of Pennsylvania), Todd W. Ridky(University of Pennsylvania)
Cited by 24
Related Papers
LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
|Cancer Research Communications|2023|9
ZIP9 is a Druggable Determinant of Sex Differences in Melanoma
|bioRxiv (Cold Spring Harbor Laboratory)|2020|4
Non-classical estrogen signaling inhibits melanoma and improves response to PD-1 blockade
|bioRxiv (Cold Spring Harbor Laboratory)|2017|2
CHRM1 is a Druggable Melanoma Target Whose Endogenous Activity is Determined by Inherited Genetic Variation in DOPA Production
|bioRxiv (Cold Spring Harbor Laboratory)|2021|0